Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Johnson and Johnson
McKinsey
Medtronic
Queensland Health
Mallinckrodt
Chubb
Federal Trade Commission
US Department of Justice
Moodys

Generated: June 22, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,632,760

« Back to Dashboard

Which drugs does patent 8,632,760 protect, and when does it expire?

Patent 8,632,760 protects LATISSE and is included in one NDA.

This patent has sixteen patent family members in seven countries.
Summary for Patent: 8,632,760
Title:Method of enhancing hair growth
Abstract: Methods and compositions for stimulating the growth of hair are disclosed wherein said compositions include a cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl compound represented by the formula I ##STR00001## wherein the dashed bonds represent a single or double bond which can be in the cis or trans configuration, A, B, Z, X, R.sub.1 and R.sub.2 are as defined in the specification. Such compositions are used in treating the skin or scalp of a human or non-human animal. Bimatoprost is preferred for this treatment.
Inventor(s): Woodward; David F. (Lake Forest, CA), VanDenburgh; Amanda M. (Huntington Beach, CA)
Assignee: Allergan, Inc. (Irvine, CA)
Application Number:13/441,783
Patent Claim Types:
see list of patent claims
Use; Composition; Formulation;

Drugs Protected by US Patent 8,632,760

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Allergan LATISSE bimatoprost SOLUTION/DROPS;TOPICAL 022369-001 Dec 24, 2008 AT RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial METHOD OF INCREASING EYELASH GROWTH ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 8,632,760

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,263,054 Method of enhancing hair growth ➤ Try a Free Trial
8,758,733 Topical treatment for chemotherapy induced eyelash loss or hypotrichosis using prostamide F2 alpha agonists ➤ Try a Free Trial
8,926,953 Method of enhancing hair growth ➤ Try a Free Trial
7,351,404 Method of enhancing hair growth ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Family Members for US Patent 8,632,760

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Japan 4143034 ➤ Try a Free Trial
Japan 2005521672 ➤ Try a Free Trial
Hong Kong 1203839 ➤ Try a Free Trial
European Patent Office 2802331 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Baxter
Queensland Health
US Department of Justice
UBS
Moodys
Harvard Business School
Cipla
Dow
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.